ACE Biosciences Divests Alphalyse in Management Buyout
News Oct 13, 2005
ACE BioSciences A/S has announced that it has divested Alphalyse A/S, it’s wholly owned, fast track protein identification subsidiary, in a management buy-out.
Under the terms of the agreement, three members of staff will leave ACE BioSciences to join Alyphalyse.
They include Dr Thomas Kofoed, formerly Head of Protein Identification at ACE BioSciences and Chief Operating Officer of Alphalyse, who will be Chief Executive Officer of the independent entity.
Ms Ingelise Saunders, ACE BioSciences’ CEO commented, "This move will ensure that both businesses receive the necessary focus, investment and management time to realize their full potential."
"ACE BioSciences is dedicated to the discovery and development of vaccines and antibodies to address infectious disorders."
"Our current therapeutic focus is travellers’ diarrhoea, where we are building a broad, competitive portfolio of projects by driving forward our internal research programmes and through the judicious in-licensing of clinical projects."
"Our Campylobacter vaccine, the first commercially available vaccine against this pathogen, will enter clinical trials in the 2nd quarter of 2006 and we are currently recruiting additional development staff to support this move."
"We are also working on a Streptococcus pneumonia vaccine, a project which we expect to partner by the end of 2005 and we are about to select lead candidates based on animal efficacy data."
"Our product pipeline is progressing on track and we plan to strengthen our discovery team, articularly in terms of our vaccine expertise, in the coming months."
Dr Thomas Kofoed, Chief Executive of Alphalyse commented, "This is a really exciting opportunity which will enable us to maximize the potential of our world-class protein identification service."
"In particular we want to expand on our unique Pick’n Post (P&P) Service: a postal protein identification option which is fast, secure, easy-to-use, and takes less than ten minutes for users to process."
"Alphalyse provides all the necessary kit and courier services for free, processes the results in less than a week and e-mails the outcome to customers: all at a very affordable price."
"We estimate that the total world market potential for P&P could be several million Euro per year."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE